5-MeO-DMT Shows Rapid Remission in a Small Postpartum Depression Trial
A small open-label trial of inhaled 5-MeO-DMT in women with postpartum depression reported remission in all 10 participants by day 8. What it shows, and its limits.
5-MeO-DMT Research
Clinical research on 5-MeO-DMT is moving quickly. Here are plain-language summaries of the studies and announcements worth knowing about, with links to the original sources.
A note before you read: these trials test pharmaceutical formulations of 5-MeO-DMT (often called mebufotenin) in clinical settings, usually without ceremony and often without therapy. They tell us a lot about the molecule. They don't describe what a ceremony with me is, and nothing here is medical advice. Where a peer-reviewed paper exists, it's linked.
Read More
5-MeO-DMT Outperforms Placebo in a Randomized Depression Trial
In a placebo-controlled trial of 81 people, single-day inhaled 5-MeO-DMT led to remission in 57.5% vs 0% on placebo. A plain-language look at the results.
5-MeO-DMT Alongside Antidepressants: An Early Trial
A 12-person trial gave intranasal 5-MeO-DMT to people staying on their SSRI antidepressant. What it found, and why it doesn't change SSRI screening in ceremony.
One Dose, Twelve Weeks: Early Results for Intranasal 5-MeO-DMT
One 10 mg dose of intranasal 5-MeO-DMT, with psychological support, lowered depression scores within a day for 12 weeks in a small open-label trial.
5-MeO-DMT for Alcohol Use Disorder: First Clinical Trial Results (BPL-003)
A 12-person open-label study paired one dose of intranasal 5-MeO-DMT with 10 weeks of relapse-prevention therapy for alcohol use disorder. Results and caveats.
US Proposes Nearly Tripling 5-MeO-DMT for Research in 2026
The US DEA proposed raising the 2026 research production quota for 5-MeO-DMT from 11,000 to 30,000 grams. What production quotas are, and what the increase signals.
A Second Dose of 5-MeO-DMT Deepens and Extends the Effect
In the extension of a 193-person trial, a second intranasal 5-MeO-DMT dose eight weeks later deepened and extended antidepressant effects. Results, side effects and caveats.
FDA Grants Breakthrough Therapy Designation to a 5-MeO-DMT Nasal Spray
The US FDA gave Breakthrough Therapy designation to BPL-003, an intranasal 5-MeO-DMT, for treatment-resistant depression. What the designation means and doesn't.
Two Doses, Two Weeks Apart: An Early Look at Repeat 5-MeO-DMT Sessions
A small study gave intranasal 5-MeO-DMT twice, two weeks apart, to people with treatment-resistant depression. Remission doubled after the second dose. Results and limits.
5-MeO-DMT in Bipolar II Depression: A First, Very Small Trial
A six-person trial of inhaled 5-MeO-DMT (GH001) in bipolar II depression found rapid improvement with no signs of mania over eight days. What it shows, and its limits.
The Largest 5-MeO-DMT Trial So Far Meets Its Goals
A 193-person blinded trial found a single intranasal 5-MeO-DMT dose reduced depression within a day, lasting eight weeks. Results, side effects and what they mean.
How Intranasal 5-MeO-DMT Works in the Body: The First Human Trial
The first trial of intranasal 5-MeO-DMT found effects peaked within minutes and faded within 90, with 60% having a complete mystical experience at higher doses.
Curious what this medicine is like in a careful, ceremonial setting? I offer private 1:1 ceremonies and Inward, a low-dose sound bath, in Victoria, BC.